BioCentury
ARTICLE | Clinical News

Sinovac vaccine meets primary in Phase III trial

March 15, 2013 12:30 AM UTC

Sinovac Biotech Ltd. (NASDAQ:SVA) said its vaccine against human enterovirus 71 (EV71) met the primary endpoint of preventing hand, foot and mouth disease (HFMD) caused by EV71 vs. placebo in a Phase ...